Verified

Research Funding Opportunity

ECD Global Alliance

The ECD Global Alliance is dedicated to enhancing all research and knowledge of Erdheim-Chester disease through supporting leading medical research. The ECD Global Alliance funds research dedicated to exploring the diagnosis, cause, treatments, and cure of Erdheim-Chester Disease.

In addition, the organization works with research teams and patients around the world to facilitate communication between the two groups.

Overview

In addition, the organization works with research teams and patients around the world to facilitate communication between the two groups.

Grant Applications and Review Process

A call for Letters of Intent (LOI) is sent out to all known avenues for dissemination and is posted on the ECD Global Alliance website. Submitted LOIs (Letters of Intent) are reviewed by a committee of qualified researchers and clinicians. The investigators submitting projects that hold the most promise for making a significant and lasting advance in the knowledge and treatment of ECD are then invited to submit a complete proposal.

A Grant Application Review (GAR) Committee made up of qualified researchers is assembled to review submitted application proposals. Individuals on the committee first review each application independently. The GAR Committee then comes together as a group to share comments and discuss each application submitted. This committee provides the ECD Global Alliance Board of Directors with a ranking order of the applications. The Board of Directors then makes the final funding decision and notifies the applicants. Letters of Intent are submitted via an LOI submission form and are reviewed per an LOI Review Process and criteria. Invited proposals are then submitted and reviewed according to the ECDGA Grant Application Process.

Current Grant Opportunities: Early Career Investigator Grant

The ECDGA announces new funding cycles every year. If you are interested in receiving information about funding cycles, please register with the organization here.

The Erdheim-Chester Disease Global Alliance is pleased to announce a funding opportunity for Erdheim-Chester Disease and adult histiocytic disorders. Up to $60,000 USD will be awarded.

AI Based Application Success Predictor

The name ECD Global Alliance can refer to different organizations. In the rare-disease research context, the likely match is the Erdheim-Chester Disease Global Alliance, which supports research into Erdheim-Chester disease (ECD), a rare histiocytic disorder. Its published grant review criteria provide a useful basis for identifying previous success predictors.

Erdheim-Chester Disease Global Alliance

Category	Details
Organization type	Non-profit disease-focused research and patient advocacy organization
Country	United States
Research area	Erdheim-Chester disease, rare histiocytic disorders, disease mechanisms, diagnosis, and treatment
Grant program	Early Career Investigator Grant; other research funding opportunities as announced
Previous success predictors	1. Significance of the research to ECD. 2. Investigator qualifications and track record. 3. Innovation and originality. 4. Scientific rigor and research methodology. 5. Feasibility, milestones, and alternative strategies. 6. Strength of the research environment and institutional support. 7. Preliminary data and relevant previous work. 8. Potential to improve ECD diagnosis, treatment, or understanding. 9. Appropriate budget and justification. 10. Complete application and required ethics approvals. erdheim-chester.org
Historical success rate	Not verified; application totals and award counts are needed to calculate it.

Excel-ready entry — Previous Success Predictors: ECD research relevance; scientific significance; investigator expertise; innovation; methodological rigor; feasibility; preliminary data; institutional support; potential clinical impact; justified budget; ethics compliance; and application completeness.

Official sources:

ECD Global Alliance — Grant Opportunities

Grant Application Review Criteria (PDF)

Note: The detailed review document is an older set of guidelines. The currently advertised 2026 Early Career Investigator Grant offers up to $60,000 for a two-year project, so applicants should check the current call for its applicable criteria.

Specialties

Rare Diseases

Eligibility Requirements

All Early Career Investigators are urged to apply.

Sponsor Details

Sponsor Institute/Organizations: ECD Global Alliance

Sponsor Type: Corporate/Non-Profit

Address: P.O. Box 775 DeRidder, LA 70634

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity